A citation-based method for searching scientific literature

Nobuhiro Hata, Masahiro Mizoguchi, Daisuke Kuga, Ryusuke Hatae, Yojiro Akagi, Yuhei Sangatsuda, Takeo Amemiya, Yuhei Michiwaki, Yutaka Fujioka, Kosuke Takigawa, Satoshi O Suzuki, Tadamasa Yoshitake, Osamu Togao, Akio Hiwatashi, Koji Yoshimoto, Koji Iihara. J Neurooncol 2020
Times Cited: 10







List of co-cited articles
39 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
70

A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Mark R Gilbert, James J Dignam, Terri S Armstrong, Jeffrey S Wefel, Deborah T Blumenthal, Michael A Vogelbaum, Howard Colman, Arnab Chakravarti, Stephanie Pugh, Minhee Won,[...]. N Engl J Med 2014
50

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Olivier L Chinot, Wolfgang Wick, Warren Mason, Roger Henriksson, Frank Saran, Ryo Nishikawa, Antoine F Carpentier, Khe Hoang-Xuan, Petr Kavan, Dana Cernea,[...]. N Engl J Med 2014
50

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
40

Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status.
Nobuhiro Hata, Koji Yoshimoto, Ryusuke Hatae, Daisuke Kuga, Yojiro Akagi, Yuhei Sangatsuda, Satoshi O Suzuki, Tadahisa Shono, Masahiro Mizoguchi, Koji Iihara. Onco Targets Ther 2017
11
40

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
30

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.
Quinn T Ostrom, Gino Cioffi, Haley Gittleman, Nirav Patil, Kristin Waite, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2019
702
30

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
30

The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma.
Shigeru Yamaguchi, Yukitomo Ishi, Hiroaki Motegi, Michinari Okamoto, Hiroyuki Kobayashi, Kenji Hirata, Yoshitaka Oda, Shinya Tanaka, Shunsuke Terasaka, Kiyohiro Houkin. J Neurosurg Sci 2020
4
75

Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis.
Hajime Yonezawa, Hirofumi Hirano, Hiroyuki Uchida, Mika Habu, Ryosuke Hanaya, Tatsuki Oyoshi, Yuko Sadamura, Tomoko Hanada, Hiroshi Tokimura, Fm Moinuddin,[...]. Mol Clin Oncol 2017
11
30

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, Victoria Wang, Yuan Qi, Matthew D Wilkerson, C Ryan Miller, Li Ding, Todd Golub, Jill P Mesirov,[...]. Cancer Cell 2010
20

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.
M Lacroix, D Abi-Said, D R Fourney, Z L Gokaslan, W Shi, F DeMonte, F F Lang, I E McCutcheon, S J Hassenbusch, E Holland,[...]. J Neurosurg 2001
20

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.
Antonio Omuro, Gordana Vlahovic, Michael Lim, Solmaz Sahebjam, Joachim Baehring, Timothy Cloughesy, Alfredo Voloschin, Shakti H Ramkissoon, Keith L Ligon, Robert Latek,[...]. Neuro Oncol 2018
190
20

The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R Salama, Siyuan Zheng, Debyani Chakravarty, J Zachary Sanborn, Samuel H Berman,[...]. Cell 2013
20

A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
Evanthia Galanis, S Keith Anderson, Erin L Twohy, Xiomara W Carrero, Jesse G Dixon, David Dinh Tran, Suriya A Jeyapalan, Daniel M Anderson, Timothy J Kaufmann, Ryan W Feathers,[...]. Cancer 2019
24
20

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Michael Weller, Nicholas Butowski, David D Tran, Lawrence D Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A Goldlust, Fabio Iwamoto,[...]. Lancet Oncol 2017
419
20

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
David A Reardon, Alba A Brandes, Antonio Omuro, Paul Mulholland, Michael Lim, Antje Wick, Joachim Baehring, Manmeet S Ahluwalia, Patrick Roth, Oliver Bähr,[...]. JAMA Oncol 2020
207
20


Current Trends and Healthcare Resource Usage in the Hospital Treatment of Primary Malignant Brain Tumor in Japan: A National Survey Using the Diagnostic Procedure Combination Database (J-ASPECT Study-Brain Tumor).
Koji Yoshimoto, Akiko Kada, Daisuke Kuga, Ryusuke Hatae, Hideki Murata, Yojiro Akagi, Kunihiro Nishimura, Ryota Kurogi, Ataru Nishimura, Nobuhiro Hata,[...]. Neurol Med Chir (Tokyo) 2016
4
50

EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
Koos E Hovinga, Heather J McCrea, Cameron Brennan, Jason Huse, Junting Zheng, Yoshua Esquenazi, Katherine S Panageas, Viviane Tabar. J Neurooncol 2019
16
20

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Thomas Sandmann, Richard Bourgon, Josep Garcia, Congfen Li, Timothy Cloughesy, Olivier L Chinot, Wolfgang Wick, Ryo Nishikawa, Warren Mason, Roger Henriksson,[...]. J Clin Oncol 2015
180
20

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny. Nat Rev Drug Discov 2004
20

Bevacizumab for glioblastoma.
Yoshitaka Narita. Ther Clin Risk Manag 2015
28
20

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
Teri N Kreisl, Lyndon Kim, Kraig Moore, Paul Duic, Cheryl Royce, Irene Stroud, Nancy Garren, Megan Mackey, John A Butman, Kevin Camphausen,[...]. J Clin Oncol 2009
20

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Walter Taal, Hendrika M Oosterkamp, Annemiek M E Walenkamp, Hendrikus J Dubbink, Laurens V Beerepoot, Monique C J Hanse, Jan Buter, Aafke H Honkoop, Dolf Boerman, Filip Y F de Vos,[...]. Lancet Oncol 2014
433
20

Lomustine and Bevacizumab in Progressive Glioblastoma.
Wolfgang Wick, Thierry Gorlia, Martin Bendszus, Martin Taphoorn, Felix Sahm, Inga Harting, Alba A Brandes, Walter Taal, Julien Domont, Ahmed Idbaih,[...]. N Engl J Med 2017
316
20

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Henry S Friedman, Michael D Prados, Patrick Y Wen, Tom Mikkelsen, David Schiff, Lauren E Abrey, W K Alfred Yung, Nina Paleologos, Martin K Nicholas, Randy Jensen,[...]. J Clin Oncol 2009
20

The Japan Neurosurgical Database: Overview and Results of the First-year Survey.
Koji Iihara, Teiji Tominaga, Nobuhito Saito, Michiyasu Suzuki, Isao Date, Yukihiko Fujii, Kazuhiro Hongo, Kiyohiro Houkin, Amami Kato, Yoko Kato,[...]. Neurol Med Chir (Tokyo) 2020
7
28

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Patrick Y Wen, David R Macdonald, David A Reardon, Timothy F Cloughesy, A Gregory Sorensen, Evanthia Galanis, John Degroot, Wolfgang Wick, Mark R Gilbert, Andrew B Lassman,[...]. J Clin Oncol 2010
20

The role of bevacizumab in the treatment of glioblastoma.
Roberto Jose Diaz, Sheikh Ali, Mehreen Gull Qadir, Macarena I De La Fuente, Michael E Ivan, Ricardo J Komotar. J Neurooncol 2017
85
20

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Hideyuki Arita, Kai Yamasaki, Yuko Matsushita, Taishi Nakamura, Asanao Shimokawa, Hirokazu Takami, Shota Tanaka, Akitake Mukasa, Mitsuaki Shirahata, Saki Shimizu,[...]. Acta Neuropathol Commun 2016
120
20

A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology.
Ryusuke Hatae, Nobuhiro Hata, Satoshi O Suzuki, Koji Yoshimoto, Daisuke Kuga, Hideki Murata, Yojiro Akagi, Yuhei Sangatsuda, Toru Iwaki, Masahiro Mizoguchi,[...]. Neuropathology 2017
23
20

Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data.
Ryusuke Hatae, Nobuhiro Hata, Koji Yoshimoto, Daisuke Kuga, Yojiro Akagi, Hideki Murata, Satoshi O Suzuki, Masahiro Mizoguchi, Koji Iihara. PLoS One 2016
27
20

Insular primary glioblastomas with IDH mutations: Clinical and biological specificities.
Nobuhiro Hata, Ryusuke Hatae, Koji Yoshimoto, Hideki Murata, Daisuke Kuga, Yojiro Akagi, Yuhei Sangatsuda, Satoshi O Suzuki, Toru Iwaki, Masahiro Mizoguchi,[...]. Neuropathology 2017
11
20

Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue.
Yukie Araki, Masahiro Mizoguchi, Koji Yoshimoto, Tadahisa Shono, Toshiyuki Amano, Akira Nakamizo, Satoshi O Suzuki, Toru Iwaki, Tomio Sasaki. Brain Tumor Pathol 2011
17
20

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
Dominik Sturm, Hendrik Witt, Volker Hovestadt, Dong-Anh Khuong-Quang, David T W Jones, Carolin Konermann, Elke Pfaff, Martje Tönjes, Martin Sill, Sebastian Bender,[...]. Cancer Cell 2012
20

Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.
Koji Yoshimoto, Ryusuke Hatae, Yuhei Sangatsuda, Satoshi O Suzuki, Nobuhiro Hata, Yojiro Akagi, Daisuke Kuga, Murata Hideki, Koji Yamashita, Osamu Togao,[...]. Brain Tumor Pathol 2017
29
20

TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.
Matthias Simon, Ismail Hosen, Konstantinos Gousias, Sivaramakrishna Rachakonda, Barbara Heidenreich, Marco Gessi, Johannes Schramm, Kari Hemminki, Andreas Waha, Rajiv Kumar. Neuro Oncol 2015
114
20

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
20

IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, Dan Rohle, Sevin Turcan, Omar Abdel-Wahab, Christopher R Edwards, Raya Khanin, Maria E Figueroa, Ari Melnick,[...]. Nature 2012
10

The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function.
David Warde-Farley, Sylva L Donaldson, Ovi Comes, Khalid Zuberi, Rashad Badrawi, Pauline Chao, Max Franz, Chris Grouios, Farzana Kazi, Christian Tannus Lopes,[...]. Nucleic Acids Res 2010
10

Radiotherapy for glioblastoma in the elderly.
Florence Keime-Guibert, Olivier Chinot, Luc Taillandier, Stéphanie Cartalat-Carel, Marc Frenay, Guy Kantor, Jean-Sébastien Guillamo, Eric Jadaud, Philippe Colin, Pierre-Yves Bondiau,[...]. N Engl J Med 2007
502
10

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.
David A Reardon, Patrick Y Wen, Annick Desjardins, Tracy T Batchelor, James J Vredenburgh. Expert Opin Biol Ther 2008
64
10

Transdifferentiation of glioblastoma cells into vascular endothelial cells.
Yasushi Soda, Tomotoshi Marumoto, Dinorah Friedmann-Morvinski, Mie Soda, Fei Liu, Hiroyuki Michiue, Sandra Pastorino, Meng Yang, Robert M Hoffman, Santosh Kesari,[...]. Proc Natl Acad Sci U S A 2011
344
10

The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling.
E J Lowenstein, R J Daly, A G Batzer, W Li, B Margolis, R Lammers, A Ullrich, E Y Skolnik, D Bar-Sagi, J Schlessinger. Cell 1992
10

New approach for understanding genome variations in KEGG.
Minoru Kanehisa, Yoko Sato, Miho Furumichi, Kanae Morishima, Mao Tanabe. Nucleic Acids Res 2019
828
10


Getting personal with neoantigen-based therapeutic cancer vaccines.
Nir Hacohen, Edward F Fritsch, Todd A Carter, Eric S Lander, Catherine J Wu. Cancer Immunol Res 2013
108
10

NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer.
Patrick S Dischinger, Elizabeth A Tovar, Curt J Essenburg, Zachary B Madaj, Eve E Gardner, Megan E Callaghan, Ashley N Turner, Anil K Challa, Tristan Kempston, Bryn Eagleson,[...]. NPJ Breast Cancer 2018
21
10



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.